StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
BWAYBullishEarningsnews
High materiality8/10

BrainsWay Reports Strong Q4 and 2025 Financial Results with Positive Outlook

Mar 11, 2026, 7:36 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The strong financial performance and bullish guidance suggest share price appreciation potential, similar to sector trends seen post-FDA approvals.

AI summary

What happened, with direct paths to the underlying reporting

BrainsWay Ltd. reported a 27% year-over-year revenue increase to $14.5 million in Q4 2025, alongside a 161% surge in net income to $7.6 million. The company anticipates a favorable growth trajectory due to recent FDA approvals and an increased performance obligation of around $70 million.

  • Q4 2025 revenue increased by 27% to $14.5 million.
  • Full year 2025 net income rose 161% to $7.6 million.
  • FDA approved new Deep TMS treatments, expanding market potential.
  • Performance obligations increased 43% to $70 million.
  • Expecting 27-30% revenue growth for full-year 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event